Sign in or Join FriendFeed
FriendFeed is the easiest way to share online. Learn more »
Libby's H*O*P*E*

Libby's H*O*P*E*

Libby's H*O*P*E* (*Helping *Ovarian Cancer Survivors *Persevere Through *Education). To learn more go to
AstraZeneca's Lynparza (olaparib) Approved in EU for Ovarian Cancer w/BRCA Gene Mutation. .... - December 19, 2014 - -
Contraception May Reduce BRCA-Associated Ovarian Cancers. ...... | Cancer Network -
FDA Approves Myriad's BRACAnalysis CDx for Use with Ovarian Cancer PARP Inhibitor Drug Lynparza (olaparib). ....... | GenomeWeb -
FDA approves Lynparza (olaparib; PARP inhibitor) to treat advanced ovarian cancer with BRCA gene mutation. .......-
Female patients with pseudomyxoma peritonei: a single-institution clinicopathologic study of 35 cases. ... - PubMed - NCBI -
Sertoli-Leydig cell tumor with heterologous element: a case report and a review of the literature. ... - PubMed - NCBI -
Long-Term Survival Metastatic Ovarian Cancer Elderly Patient. ..... - PubMed - NCBI -
Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer....... - PubMed - NCBI -
In parallel, initial data reported here from an ongoing Phase 2 clinical study of CRLX101 monotherapy shows measurable tumor reductions in 74% of patients and a 16% RECIST response rate to date. Conclusions: Given these preclinical and initial clinical results, further clinical studies are currently evaluating CRLX101 in combination with bevacizumab in ovarian cancer and warrant the evaluation of this therapy combination in other cancer types where HIF-1α is implicated in pathogenesis, as it may potentially be able to improve the efficacy of anti-angiogenic drugs. - Libby's H*O*P*E*
Very late recurrence (after more than 20 years) of epithelial ovarian carcinoma: case report and literature review.... - PubMed - NCBI -
Past, present and future targets for immunotherapy in ovarian cancer. .......- PubMed - NCBI -
PharmaMar reports promising Phase IIb overall survival data for use of PM1183 in platinum-resistant ovarian cancer pts. ......-
In this multicenter Phase IIb randomized trial, platinum-resistant ovarian patients treated with PM1183 lived longer, with a median overall survival of 18.1 months, compared to topotecan, which only achieves 8.5 months. PharmaMar will launch a pivotal Phase III trial to confirm the efficacy of PM1183 in a larger population, and that is expected to be the final step before registration of PM1183 for platinum-resistant ovarian cancer. - Libby's H*O*P*E*
Ovarian cancer uses abdominal stem cells to fuel growth and metastasis. .... -
Virus May Be Active Against Advanced Ovarian Cancer. ..... | Cancer Network -
26th EORTC-NCI-AACR Symposium: Researchers identify biological indicator of response to new ovarian cancer drug. .... | Science Codex -
Ovarian clear cell cancer patients may benefit from pelvic radiotherapy. .... | Loyola Medicine -
Salpingectomy associated with reduced ovarian cancer risk. ..... : OBGYN News -
Doctors explain how they will cut risk of ovarian cancer: Fallopian tubes could be removed once women have completed their families. .....  | Daily Mail Online -
M.D. Anderson uses math formula to help in fight against ovarian cancer. .... - Houston Chronicle -
Clinicopathological heterogeneity in ovarian clear cell adenocarcinoma: a study on individual therapy practice.... - PubMed - NCBI -
Leukemia drug cirmtuzumab (ROR1 inhibitor) may be effective against ovarian cancer stem cells......
Pfizer, Germany’s strike deal to develop cancer tumor anti-PD-L1 immunotherapy treatment. ...... - MarketWatch -
FDA Approves Genentech’s Avastin (Bevacizumab) Plus Chemotherapy to Treat Women with Platinum-Resistant Recurrent Ovarian Cancer. ..... -
FDA Approves Roche's Avastin for Ovarian Cancer. ..... - ABC News -
MTV Reality Star Diem Brown Dies at 32 from ovarian cancer. ..... - ABC News -
Epic Sciences to Present on Characterizing PD-L1 in Circulating Tumor Cells at the 26th EORTC-NCI-AACR Symposium. ...... -
Blueprint Medicines to Present Discovery of New Cancer Drug Targets at EORTC-NCI-AACR Symposium. .......Blueprint Medicines News Release -
Amgen Announces Top-Line Secondary Endpoint Results Of Phase 3 Trebananib TRINOVA-1 Trial In Patients With Recurrent Ovarian Cancer - Study Failed to Meet Secondary Endpoint of Overall Survival. ...........Amgen - Media - News Release -
Oxigene Faces Challenges for Ovarian Cancer Drug Even With Encouraging Data. ..... - TheStreet -
Promising Prognostic Biomarker Candidates for Ovarian Cancer Uncovered by Roswell Park Team. ..... -
UConn Researchers Develop Personalized Ovarian Cancer Vaccines. ...... | UConn Today -
Other ways to read this feed:Feed readerFacebook